Key Highlights
- Amgen will trade ex-dividend on August 21, 2026, ahead of a $2.52 per-share quarterly payment due September 11.
- The $10.08 annualized Dividend yields approximately 2.28% at current share price levels.
- Second-quarter 2026 Revenue reached $10.054 billion, with GAAP EPS of $4.37 and non-GAAP EPS of $6.29.
- Free Cash Flow was approximately $3.5 billion for the quarter, comfortably covering the dividend.
Dividend Program and Shareholder Returns
Amgen (NASDAQ:AMGN) shares will go ex-dividend on August 21, 2026, ahead of a quarterly payment of $2.52 per share scheduled for September 11. Shareholders of record as of August 21 will receive the payout, which equals $10.08 on an annualized basis. The company confirmed in its latest quarterly filing that $2.52 dividends were declared for both the first and second quarters of 2026, paid in March and June respectively, indicating consistency in the current payout level. The dividend also reflects a 6% increase from the prior-year rate.
At current market prices, the annualized dividend implies a yield of approximately 2.28%. That places Amgen among the moderate-income names in large-cap pharmaceuticals, rather than a high-yield vehicle. The distribution is well supported by the company's free cash flow generation, though investors should keep the payout in context alongside Amgen's Debt load and continued research spending.
About the Company
Amgen is a global biotechnology company that discovers, develops, and manufactures medicines for serious illnesses, with a portfolio spanning oncology, cardiovascular disease, inflammation, bone health, and rare diseases. The company's scale exposes it to sector-wide risks common to large pharmaceutical firms, including Patent expirations, biosimilar competition, and regulatory uncertainty tied to new drug approvals.
Financial Performance Behind the Payout
Amgen's second-quarter 2026 results showed revenue of $10.054 billion, up from $9.179 billion a year earlier. GAAP Net Income was $2.375 billion, versus $1.432 billion in the prior-year period, while GAAP diluted EPS came in at $4.37. Non-GAAP EPS was notably higher at $6.29, reflecting adjustments that investors should treat separately from the GAAP figure when assessing underlying dividend coverage.
Free cash flow of approximately $3.5 billion for the quarter provides a substantial cushion relative to the dividend outlay. The company's Return on Equity is unusually elevated due to its capital structure, a detail that should not be read in isolation as a signal of exceptional underlying profitability.
Guidance and Pipeline Developments
Management updated full-year 2026 guidance to revenue of $38.2 billion to $39.4 billion and GAAP EPS of approximately $15.80 to $17.08. The upgrade reflects continued strength in Amgen's established medicines portfolio and newer product contributions. The company also disclosed a European approval for IMDYLLTRA in lung cancer, a positive regulatory milestone, while flagging approval related uncertainty tied to TAVNEOS.
These pipeline items matter for dividend durability over the longer term. Amgen remains a large, diversified biotech, but individual products still carry outsized influence on revenue, and biosimilar competition remains a structural risk to monitor.
Outlook
Amgen's combination of raised guidance, strong free cash flow, and a steady $2.52 quarterly payout suggests the dividend remains on solid footing heading into the September payment. The wide gap between GAAP EPS of $4.37 and non-GAAP EPS of $6.29 is worth watching each quarter, as is the pace of biosimilar erosion against key products. For now, cash generation appears more than sufficient to sustain, and potentially grow, the payout, provided pipeline execution continues and debt levels remain manageable.

_09_30_2026_02_08_20_566201.jpg)




Please wait processing your request...